PALI Palisade Bio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PALI matters now
Palisade Bio, Inc. (PALI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.96 with -0.51% on the session and $340.2M in market capitalization; recent performance reads 1-month +3.31% and YTD -20.43%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-9.6M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.
The latest indexable market news headline is "Palisade Bio to Participate in the Leerink Partners Therapeutics Forum" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $1.50; recent insider activity includes Baltera Robert Jr. filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.08
P/S
0.00
EV/EBITDA
-7.55
DCF Value
$2.39
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.8%
ROA
-18.1%
ROIC
-20.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-9.6M | $-0.05 |
| Q4 2025 | $0.00 | $-8.9M | $-0.06 |
| FY 2025 | $0.00 | $-16.8M | $-0.30 |
| Q3 2025 | $0.00 | $-2.9M | $-0.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$1.50
Target (Median)
$1.50
Target Range
$1.50 - $1.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.54
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.